Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
Yu J, Kim Y, Mehta R, Miao R, Strosberg J, Imanirad I, Kim D, Kim R. Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC). Journal Of Clinical Oncology 2023, 41: 188-188. DOI: 10.1200/jco.2023.41.4_suppl.188.Peer-Reviewed Original ResearchPathway enrichment analysisReceptor signaling pathwayEnrichment analysisProgressive diseaseB cell activationGene OntologyCell-substrate junction assemblySignaling pathwayGO pathway enrichment analysisPositive regulation of B cell activationDownregulated pathwaysKyoto Encyclopedia of GenesSerine-type endopeptidase activityPredictive biomarkersMSS-CRCKEGG pathway enrichment analysisRegulation of B cell activationECM-receptor interactionTumor samplesEncyclopedia of GenesColorectal cancerGenomes (KEGGExtracellular matrixPre-treatment tumor samplesGene set enrichment analysisBiomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Miao R, Kim D, Yu J, Kovari B, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. Journal Of Clinical Oncology 2023, 41: 228-228. DOI: 10.1200/jco.2023.41.4_suppl.228.Peer-Reviewed Original ResearchProgression free survivalMedian progression free survivalTreated with regorafenibOverall survivalPD-L1Tumor microenvironmentColorectal cancerMedian OSCD8 expressionPartial responseTreg cellsImmune desertPredictive biomarkersAssociated with prolonged progression free survivalMismatch repair-proficient colorectal cancersProlonged progression free survivalDisease control ratePhase I/Ib studyPredicting clinical benefitPD-L1 expressionPretreatment tumor samplesPotential predictive biomarkersPMMR colorectal cancerBiomarker-positiveBiomarker-negative patients